Time to recurrence
Single‐dose, preoperative MMC‐EMDA probably leads to lower time to recurrence compared with single‐dose, postoperative MMC‐PD (moderate certainty).
1 finding from 1 review
Time to progression
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes time to progression compared with single‐dose, postoperative MMC‐PD (very low certainty).
1 finding from 1 review
Serious adverse events
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes serious adverse events compared with single‐dose, postoperative MMC‐PD (very low certainty).
1 finding from 1 review
Disease‐specific survival
Single‐dose, preoperative MMC‐EMDA showed no clear difference in disease‐specific survival compared with single‐dose, postoperative MMC‐PD (low certainty).
1 finding from 1 review
Disease‐specific quality of life ‐ not reported
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to bladder cancer recurrence (absolute effect size estimates based on recurrence rate at 12 months)
Single‐dose intravesical chemotherapy instillation may leads to lower time to bladder cancer recurrence (absolute effect size estimates… compared with placebo or observation after nephroureterectomy (low certainty).
1 finding from 1 review
Time to death from UTUC5
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events
1 finding from 1 review
Time to death from any cause5
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor adverse events
1 finding from 1 review
Disease‐specific quality of life
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to recurrence
Single‐dose, preoperative MMC‐EMDA probably leads to lower time to recurrence compared with TURBT alone (moderate certainty).
1 finding from 1 review
Time to progression
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes time to progression compared with TURBT alone (very low certainty).
1 finding from 1 review
Serious adverse events
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes serious adverse events compared with TURBT alone (very low certainty).
1 finding from 1 review
Disease‐specific survival
Single‐dose, preoperative MMC‐EMDA showed no clear difference in disease‐specific survival compared with TURBT alone (moderate certainty).
1 finding from 1 review
Disease‐specific quality of life ‐ not reported
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found